MK-8189 Panel A for Schizophrenia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
California Clinical Trials Medical Group managed by PAREXEL ( Site 0002), Glendale, CA
Schizophrenia
MK-8189 - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

The primary purpose of this study is to assess the safety and tolerability of multiple ascending doses of MK-8189 in participants with schizophrenia.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Schizophrenia

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Up to 18 days

Up to 18 days
Number of participants experiencing an Adverse Event (AE)
Up to 4 days
Number of participants discontinuing study treatment due to an AE

Trial Safety

Safety Progress

1 of 3

Other trials for Schizophrenia

Side Effects for

MK-8189
18%Akathisia
16%Nausea
16%Headache
9%Dystonia
8%Sedation
8%Vomiting
8%Diarrhoea
8%Anxiety
7%Decreased appetite
7%Insomnia
7%Somnolence
6%Dyspepsia
3%Dizziness
2%Weight increased
2%Fatigue
1%Lethargy
1%Agitation
0%Otitis externa
0%Psychotic disorder
0%Alcohol poisoning
0%Schizophrenia
This histogram enumerates side effects from a completed 2018 Phase 2 trial (NCT03055338) in the MK-8189 ARM group. Side effects include: Akathisia with 18%, Nausea with 16%, Headache with 16%, Dystonia with 9%, Sedation with 8%.

Trial Design

6 Treatment Groups

MK-8189 Panel A
1 of 6
MK-8189 Panel B
1 of 6
MK-8189 Panel D
1 of 6
MK-8189 Panel C
1 of 6
MK-8189 Panel E
1 of 6
Placebo
1 of 6
Experimental Treatment
Non-Treatment Group

54 Total Participants · 6 Treatment Groups

Primary Treatment: MK-8189 Panel A · Has Placebo Group · Phase 1

MK-8189 Panel A
Drug
Experimental Group · 1 Intervention: MK-8189 · Intervention Types: Drug
MK-8189 Panel B
Drug
Experimental Group · 1 Intervention: MK-8189 · Intervention Types: Drug
MK-8189 Panel D
Drug
Experimental Group · 1 Intervention: MK-8189 · Intervention Types: Drug
MK-8189 Panel C
Drug
Experimental Group · 1 Intervention: MK-8189 · Intervention Types: Drug
MK-8189 Panel E
Drug
Experimental Group · 1 Intervention: MK-8189 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MK-8189
2020
Completed Phase 2
~440

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 18 days
Closest Location: California Clinical Trials Medical Group managed by PAREXEL ( Site 0002) · Glendale, CA
N/AFirst Recorded Clinical Trial
1 TrialsResearching Schizophrenia
0 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.